3:1 Bonus issue: Company announces record date for bonus shares; stock gains over 12,000 per cent, complete details inside!

The company's shares have delivered an impressive return of over 2,200 per cent to their shareholders in the past 5 years.

In a significant development, this Small-Cap company specializes in trading advanced pharmaceutical intermediates and other pharma products. The company trades and sells API intermediates (KSMs & CRMs) and various raw materials used in API production, catering to innovator and generic pharmaceutical players in domestic and international markets. Remedium Lifecare was incorporated in 1988. The company has announced the record date for the bonus issue.

According to the press release the company announced that it has set the record date as Saturday, July 6, 2024, to determine the shareholders eligible for bonus equity shares. The bonus will be issued in a ratio of 3:1, meaning shareholders will receive three fully paid equity shares of Re 1 each for each fully paid equity share of Re 1 held as of the record date.

On Friday the company’s stock closed the day at Rs 77.30 per share on the BSE representing an almost flat closing of 0.51 per cent. Additionally, the stock has delivered a multibagger return of over 2228 per cent in the past 3 years only.

As per Quarterly Results in Q4 FY24, the company reported a quarterly revenue from operation of Rs 1408 crore compared to a revenue of Rs 1834 crore, representing a de-growth on a YoY basis. The net loss of the company stood at Rs 54 crore in Q4 FY24 compared to a net loss of Rs 5 crore.

Turning attention to the annual performance of the company, it reported a revenue of Rs 4042 crore, compared to Rs 510 crore in FY23 representing a gain of 693 per cent YoY. Moreover, the company’s net profit stood at Rs 33 crore in FY24 compared to the profit of Rs 5 crore representing a gain of 560 per cent YoY.

According to the shareholding pattern, the company's promoters hold 1.11 per share while the public or retail investors hold 98.85 per share.

Investors must keep this small-cap stock on their radar.

Disclaimer: The article is for informational purposes only and not investment advice.